Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

The myGenes Study:Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

The purpose of this study is to understand the effectiveness of pharmacogenomic testing in using antidepressants and to understand how EHR - driven clinical decision support system can be used to deliver PGx test results by healhcare providers.

Inclusion Criteria:

Patients who quality the criteria below:

• Patients with nonpsychotic MDD
• Patients who would like to either start a new antidepressant or change their existing antidepressant treatment
• Patients for whom antidepressant treatment is deemed appropriate by the treating clinician
• >18 years of age
• Willingness to provide signed informed consent to participate in the study
• Will be following up or continuously visiting their physician

Providers:

• Outpatient practice providers
• Providers who are familiar with Epic

Exclusion Criteria:

Patients:

• Patients with medical contraindications that preclude antidepressant treatment
• Patients with schizophrenia, schizoaffective disorder, or who have Bipolar I disorder
• Patients currently on antipsychotic medications (e.g., typical and atypical antipsychotic drugs) and mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants)
• Patients who are pregnant or have severe cognitive impairment
• Patients requiring urgent care or inpatient hospitalization at the time of consent

Providers:

• Unable or unwilling to commit time to introduce myGenes study to patients